JERRY R. MITCHELL, M.D., Ph.D.; HYMAN J. ZIMMERMAN, M.D.; KAMAL G. ISHAK, M.D., Ph.D.; UNNUR P. THORGEIRSSON, M.D.; JOHN A. TIMBRELL, Ph.D.; WAYNE R. SNODGRASS, M.D.; SIDNEY D. NELSON, Ph.D.
The clinical spectrum of isoniazid-induced liver injury seems to be clinically, biochemically, and histologically indistinguishable from viral hepatitis, except that the injury occurs primarily in persons older than 35 years. A possible relation between susceptibility of patients to isoniazid liver injury and rapid metabolism (acetylation) of the drug has been found. Examination of isoniazid metabolites showed that patients with rapid acetylator phenotype hydrolyze much more isoniazid to isonicotinic acid and the free hydrazine moiety than do slow acetylators. The hydrazine moiety liberated from isoniazid is primarily acetylhydrazine, and studies in animals show this metabolite to be converted to a potent acylating agent that produces liver necrosis. It seems likely that formation of chemically reactive metabolites is also the biochemical event initiating isoniazid liver injury in man. Recognition of the seriousness of isoniazid hepatic injury, not readily accepted at first, has led to revisions in the uses of isoniazid prophylaxis.
MITCHELL JR, ZIMMERMAN HJ, ISHAK KG, THORGEIRSSON UP, TIMBRELL JA, SNODGRASS WR, et al. Isoniazid Liver Injury: Clinical Spectrum, Pathology, and Probable Pathogenesis. Ann Intern Med. ;84:181–192. doi: 10.7326/0003-4819-84-2-181
Download citation file:
Published: Ann Intern Med. 1976;84(2):181-192.
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use